The Full ASGCT 27th Annual Meeting Abstracts Collection is NOW LIVE! Click here to read the full collection.
More gene and RNA therapies were approved in Q3 than in each of the previous quarters for over a year.
The third quarterly report of 2022 from ASGCT and Citeline (formerly Informa Pharma Intelligence) is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
Highlights from this issue include:
Approval of two gene therapies in the EU and two more in the U.S.
CAR T-cell therapy continuing to dominate the pipeline of genetically modified cell therapies
An increase of 11 percent in dealmaking and jumps in partnerships and fundraising
Download the Full Report
Click any of the samples below to view the full report:
May 7-11, 2024 | Baltimore, MD
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico